Cellceutix Investors See Red Flags in Drug Study

Cellceutix Investors See Red Flags in Drug Study

Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment

Actelion Shares Top Swiss Market Despite Opsumit Drug Test Disappointment

Rite Aid Takes a Beating After Report of Walgreens Deal Fears

Rite Aid Takes a Beating After Report of Walgreens Deal Fears

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Celgene Could Skyrocket by 22% With Ease

Celgene Could Skyrocket by 22% With Ease

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

Odds of Surgery Partners' Takeout Grow

Odds of Surgery Partners' Takeout Grow

GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open

GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open

Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug

Trump Administration Isn't ' Pulling the Rug

Trump Administration Isn't ' Pulling the Rug" from Anyone, Says HHS Pick Price